Response of pancreatic cancer cells treated with interferon-α or β and co-exposed to ionising radiation

被引:9
作者
Joest, Eva [1 ]
Roos, Wynand P. [1 ]
Kaina, Bernd [1 ]
Schmidberger, Heinz [2 ]
机构
[1] Univ Med Mainz, Inst Toxicol, D-55131 Mainz, Germany
[2] Univ Med Mainz, Dept Radiooncol, D-55131 Mainz, Germany
关键词
interferon-alpha; interferon-beta; ionising radiation; pancreatic cancer; radiosensitisation and radioprotection; JAK-STAT PATHWAY; IN-VITRO; CARCINOMA; GROWTH; LINES; CHEMORADIOTHERAPY; RECEPTOR; CHEMORADIATION; ADENOCARCINOMA; CHEMOTHERAPY;
D O I
10.3109/09553002.2010.481321
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose: Clinical trials on pancreatic cancer demonstrated that interferons (IFN) improve the therapeutic index of combined radio- and chemotherapy. This is believed to be due to radiosensitisation of cells, which, however, needs experimental verification. Materials and methods: Here, we compared the survival response of ten pancreatic tumour cell lines following ionising radiation (IR), interferon-alpha (IFN-alpha), interferon-beta (IFN-beta) and combined treatment. The effect of combination treatment on apoptosis induction was also determined. Results: In most cell lines IFN treatment on its own exerted cytotoxicity, which was independent of the expression level of the IFN receptor on the cell surface. Three cell lines showed a radiosensitisation effect while two showed radioprotection. Although IFN-alpha is commonly used in the clinic, IFN-beta induced a stronger cytotoxic response than IFN-alpha in vitro. The likely mechanism of enhancement of radiosensitivity in the responsive cell lines was shown to be an increase of the radiation-induced apoptotic response by IFN pretreatment. Conclusions: Given that the in vitro data do not conform to the impressive clinical results observed after combined radio- and chemotherapy with IFN-alpha, it is reasonable to conclude that the sensitising effect of IFN is not mediated through modulating the intrinsic radiosensitivity of pancreatic cancer cells.
引用
收藏
页码:732 / 741
页数:10
相关论文
共 35 条
[1]   Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells [J].
Abbott, DW ;
Freeman, ML ;
Holt, JT .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (13) :978-985
[2]   COMPARATIVE-ANALYSIS OF MUTATIONS IN THE P53 AND K-RAS GENES IN PANCREATIC-CANCER [J].
BERROZPE, G ;
SCHAEFFER, J ;
PEINADO, MA ;
REAL, FX ;
PERUCHO, M .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (02) :185-191
[3]  
BORDEN EC, 1982, CANCER RES, V42, P4948
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]   EVIDENCE THAT TYPE-I AND TYPE-II INTERFERONS HAVE DIFFERENT RECEPTORS [J].
BRANCA, AA ;
BAGLIONI, C .
NATURE, 1981, 294 (5843) :768-770
[6]  
BUDILLON A, 1991, CANCER RES, V51, P1294
[7]   EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-α-mediated apoptosis in epidermoid cancer cells [J].
Caraglia, M ;
Tagliaferri, P ;
Marra, M ;
Giuberti, G ;
Budillon, A ;
Di Gennaro, E ;
Pepe, S ;
Vitale, G ;
Improta, S ;
Tassone, P ;
Venuta, S ;
Bianco, AR ;
Abbruzzese, A .
CELL DEATH AND DIFFERENTIATION, 2003, 10 (02) :218-229
[8]   ALPHA-INTERFERON POTENTIATES EPIDERMAL GROWTH-FACTOR RECEPTOR-MEDIATED EFFECTS ON HUMAN EPIDERMOID CARCINOMA KB CELLS [J].
CARAGLIA, M ;
LEARDI, A ;
CORRADINO, S ;
CIARDIELLO, F ;
BUDILLON, A ;
GUARRASI, R ;
BIANCO, AR ;
TAGLIAFERRI, P .
INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (03) :342-347
[9]   The human type I interferon receptor - Identification of the interferon beta-specific receptor-associated phosphoprotein [J].
Croze, E ;
RussellHarde, D ;
Wagner, TC ;
Pu, HF ;
Pfeffer, LM ;
Perez, HD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (52) :33165-33168
[10]   Interferon-β is more potent than interferon-α in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs [J].
Damdinsuren, B ;
Nagano, H ;
Sakon, M ;
Kondo, M ;
Yamamoto, T ;
Umeshita, K ;
Dono, K ;
Nakamori, S ;
Monden, M .
ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (10) :1184-1190